BioCardia, Inc. Reports Smaller Q3 Loss, Surpassing Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 13 2025
0mins
Should l Buy BCDA?
Source: NASDAQ.COM
Earnings Performance: BioCardia, Inc. reported a loss of $1.48 million for the third quarter, an improvement from a loss of $1.74 million in the same period last year.
Earnings Per Share: The company's earnings per share (EPS) were -$0.24, compared to -$0.61 in the previous year, beating analysts' expectations of -$0.25 per share.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BCDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BCDA
Wall Street analysts forecast BCDA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.190
Low
6.00
Averages
15.50
High
25.00
Current: 1.190
Low
6.00
Averages
15.50
High
25.00
No data
About BCDA
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BioCardia Submits Heart Failure Study Data for Accelerated Approval
- Clinical Study Progress: BioCardia has submitted data from its CardiAMP heart failure clinical study to the U.S. FDA and formally requested a meeting to discuss an accelerated approval pathway, expected to occur this quarter, demonstrating the company's strong confidence in bringing its product to market quickly.
- Significant Efficacy: In the CardiAMP heart failure trial involving 125 patients, a subgroup with elevated heart stress biomarkers showed a 47% relative risk reduction in all-cause cardiac death and a 37% relative risk reduction in non-fatal major adverse cardiac events, indicating substantial clinical benefits for high-risk patients.
- Quality of Life Improvement: Patients reported meaningful improvements in quality of life (p=0.04), which not only enhances patient experience but also provides strong support for the market potential of CardiAMP therapy, likely attracting more investor interest.
- Key FDA Meeting: The upcoming FDA meeting will determine whether BioCardia's data package is sufficient for accelerated approval, with the company focusing on emphasizing its strong safety profile and benefits observed in high-risk patients, potentially laying the groundwork for future market performance.
See More
BioCardia Submits FDA Accelerated Approval Request for CardiAMP System
- Clinical Data Submission: BioCardia has submitted CardiAMP HF clinical study data to the FDA and plans to meet with the agency this quarter to discuss the accelerated approval pathway for the CardiAMP System, marking a significant milestone in the company's cardiovascular treatment efforts.
- Significant Patient Benefits: Results from the CardiAMP HF trial involving 125 ischemic chronic heart failure patients indicate a 47% relative risk reduction in cardiac death and a 37% reduction in major adverse cardiac events for high-risk patients, demonstrating treatment efficacy and potentially expediting FDA approval.
- Breakthrough Designation: The CardiAMP System has received FDA Breakthrough Designation, highlighting its potential in heart failure treatment; BioCardia aims to gain FDA feedback on safety and clinical response data during the upcoming meeting to accelerate product launch.
- Broad Market Potential: BioCardia's CardiAMP cell therapy aims to improve cardiac microvascular function through a minimally invasive procedure, and with positive FDA feedback anticipated, the company expects significant market opportunities and revenue growth ahead.
See More
BioCardia Reports Financials and Clinical Trial Progress
- Financial Overview: BioCardia Inc (NASDAQ:BCDA) reported a slight increase in net loss to $8.2 million for 2025, reflecting ongoing financial challenges, although cash and cash equivalents rose slightly to $2.5 million, indicating stable resource management.
- R&D Expense Growth: Research and development expenses increased by 13% to $5 million in 2025, primarily due to trial closeout activities and regulatory efforts, which could strain financial resources and impact future investment capabilities.
- Clinical Trial Progress: BioCardia has made positive strides with its CardiAM therapy for heart disease, showing statistically significant improvements in heart function with p-values of 0.02 and 0.01, indicating potential for market entry.
- Regulatory Engagement and Market Outlook: The company is actively engaging with the FDA and Japan's PMDA for potential therapy approval, and while enrollment in the HF2 trial is progressing slowly, strong data support will drive future regulatory discussions and trial recruitment.
See More
BioCardia Q4 2025 Earnings Call Insights
- Clinical Trial Data: CEO Peter Altman highlighted that BioCardia has complete data from three clinical trials of CardiAMP cell therapy, with the latest Phase III results showing significant reductions in left ventricular volume during both diastole and systole, with p-values of 0.06 and 0.09, indicating clinically meaningful and statistically significant treatment effects.
- R&D Expense Growth: CFO David McClung reported total expenses of $8.3 million for 2025, reflecting a year-over-year increase of approximately 3%, with R&D expenses reaching $5 million, demonstrating the company's ongoing commitment to advancing therapeutic candidates.
- Cash Flow Status: BioCardia reported a net loss of $8.2 million for 2025, with approximately $7.5 million used in operations, and year-end cash and equivalents totaling $2.5 million, indicating the company's efforts to manage cash burn effectively.
- Regulatory Progress Expectations: Management anticipates soon submitting the Q-sub request for the CardiAMP system to the FDA, with a 45-day turnaround expected for feedback under breakthrough designation, which could significantly enhance the company's market access prospects.
See More
BioCardia Reports FY 2025 Financial Results with Increased Losses
- Financial Performance: BioCardia reported a FY 2025 GAAP EPS of -$1.23, missing estimates by $0.03, indicating ongoing challenges in profitability that may affect investor confidence.
- Operating Cash Flow: The net cash used in operations for FY 2025 was approximately $7.4 million, a decrease from $7.9 million in 2024, primarily due to the timing of supplier payments, reflecting an improvement in cash flow management.
- Cash Reserves: As of the end of 2025, the company had cash and cash equivalents totaling approximately $2.5 million, which, despite the cash flow improvement, raises concerns about liquidity to support future operations and growth.
- Net Loss Situation: The net loss for FY 2025 modestly increased to approximately $8.2 million compared to $7.9 million in 2024, indicating ongoing challenges in cost control and revenue enhancement that may impact long-term sustainability.
See More
BioCardia to Report Financial Results on March 24, 2026
- Earnings Call Announcement: BioCardia will provide its financial results for the year ended December 31, 2025, during a conference call on March 24, 2026, at 4:30 PM EDT, highlighting advancements in therapies for cardiovascular and pulmonary diseases.
- Participation Details: Registered participants can obtain their dial-in numbers via the provided link, while those unregistered can listen by calling 1-833-316-0559 in the U.S. or 1-412-317-5730 internationally, with a recommendation to join the call 10 minutes early for smooth access.
- Webcast and Replay Availability: The conference call will be available via live webcast, and a replay will be accessible approximately one hour after the call ends, allowing investors who cannot attend live to stay informed and enhancing corporate transparency.
- Company Overview: BioCardia focuses on developing cellular and cell-derived therapeutics for heart disease, with its CardiAMP and CardiALLO platforms utilizing Helix and Morph technologies to improve treatment outcomes for heart failure and acute myocardial infarction.
See More
BioCardia Submits Heart Failure Study Data for Accelerated Approval
- Clinical Study Progress: BioCardia has submitted data from its CardiAMP heart failure clinical study to the U.S. FDA and formally requested a meeting to discuss an accelerated approval pathway, expected to occur this quarter, demonstrating the company's strong confidence in bringing its product to market quickly.
- Significant Efficacy: In the CardiAMP heart failure trial involving 125 patients, a subgroup with elevated heart stress biomarkers showed a 47% relative risk reduction in all-cause cardiac death and a 37% relative risk reduction in non-fatal major adverse cardiac events, indicating substantial clinical benefits for high-risk patients.
- Quality of Life Improvement: Patients reported meaningful improvements in quality of life (p=0.04), which not only enhances patient experience but also provides strong support for the market potential of CardiAMP therapy, likely attracting more investor interest.
- Key FDA Meeting: The upcoming FDA meeting will determine whether BioCardia's data package is sufficient for accelerated approval, with the company focusing on emphasizing its strong safety profile and benefits observed in high-risk patients, potentially laying the groundwork for future market performance.
See More
BioCardia Submits FDA Accelerated Approval Request for CardiAMP System
- Clinical Data Submission: BioCardia has submitted CardiAMP HF clinical study data to the FDA and plans to meet with the agency this quarter to discuss the accelerated approval pathway for the CardiAMP System, marking a significant milestone in the company's cardiovascular treatment efforts.
- Significant Patient Benefits: Results from the CardiAMP HF trial involving 125 ischemic chronic heart failure patients indicate a 47% relative risk reduction in cardiac death and a 37% reduction in major adverse cardiac events for high-risk patients, demonstrating treatment efficacy and potentially expediting FDA approval.
- Breakthrough Designation: The CardiAMP System has received FDA Breakthrough Designation, highlighting its potential in heart failure treatment; BioCardia aims to gain FDA feedback on safety and clinical response data during the upcoming meeting to accelerate product launch.
- Broad Market Potential: BioCardia's CardiAMP cell therapy aims to improve cardiac microvascular function through a minimally invasive procedure, and with positive FDA feedback anticipated, the company expects significant market opportunities and revenue growth ahead.
See More
BioCardia Reports Financials and Clinical Trial Progress
- Financial Overview: BioCardia Inc (NASDAQ:BCDA) reported a slight increase in net loss to $8.2 million for 2025, reflecting ongoing financial challenges, although cash and cash equivalents rose slightly to $2.5 million, indicating stable resource management.
- R&D Expense Growth: Research and development expenses increased by 13% to $5 million in 2025, primarily due to trial closeout activities and regulatory efforts, which could strain financial resources and impact future investment capabilities.
- Clinical Trial Progress: BioCardia has made positive strides with its CardiAM therapy for heart disease, showing statistically significant improvements in heart function with p-values of 0.02 and 0.01, indicating potential for market entry.
- Regulatory Engagement and Market Outlook: The company is actively engaging with the FDA and Japan's PMDA for potential therapy approval, and while enrollment in the HF2 trial is progressing slowly, strong data support will drive future regulatory discussions and trial recruitment.
See More
BioCardia Q4 2025 Earnings Call Insights
- Clinical Trial Data: CEO Peter Altman highlighted that BioCardia has complete data from three clinical trials of CardiAMP cell therapy, with the latest Phase III results showing significant reductions in left ventricular volume during both diastole and systole, with p-values of 0.06 and 0.09, indicating clinically meaningful and statistically significant treatment effects.
- R&D Expense Growth: CFO David McClung reported total expenses of $8.3 million for 2025, reflecting a year-over-year increase of approximately 3%, with R&D expenses reaching $5 million, demonstrating the company's ongoing commitment to advancing therapeutic candidates.
- Cash Flow Status: BioCardia reported a net loss of $8.2 million for 2025, with approximately $7.5 million used in operations, and year-end cash and equivalents totaling $2.5 million, indicating the company's efforts to manage cash burn effectively.
- Regulatory Progress Expectations: Management anticipates soon submitting the Q-sub request for the CardiAMP system to the FDA, with a 45-day turnaround expected for feedback under breakthrough designation, which could significantly enhance the company's market access prospects.
See More
BioCardia Reports FY 2025 Financial Results with Increased Losses
- Financial Performance: BioCardia reported a FY 2025 GAAP EPS of -$1.23, missing estimates by $0.03, indicating ongoing challenges in profitability that may affect investor confidence.
- Operating Cash Flow: The net cash used in operations for FY 2025 was approximately $7.4 million, a decrease from $7.9 million in 2024, primarily due to the timing of supplier payments, reflecting an improvement in cash flow management.
- Cash Reserves: As of the end of 2025, the company had cash and cash equivalents totaling approximately $2.5 million, which, despite the cash flow improvement, raises concerns about liquidity to support future operations and growth.
- Net Loss Situation: The net loss for FY 2025 modestly increased to approximately $8.2 million compared to $7.9 million in 2024, indicating ongoing challenges in cost control and revenue enhancement that may impact long-term sustainability.
See More
BioCardia to Report Financial Results on March 24, 2026
- Earnings Call Announcement: BioCardia will provide its financial results for the year ended December 31, 2025, during a conference call on March 24, 2026, at 4:30 PM EDT, highlighting advancements in therapies for cardiovascular and pulmonary diseases.
- Participation Details: Registered participants can obtain their dial-in numbers via the provided link, while those unregistered can listen by calling 1-833-316-0559 in the U.S. or 1-412-317-5730 internationally, with a recommendation to join the call 10 minutes early for smooth access.
- Webcast and Replay Availability: The conference call will be available via live webcast, and a replay will be accessible approximately one hour after the call ends, allowing investors who cannot attend live to stay informed and enhancing corporate transparency.
- Company Overview: BioCardia focuses on developing cellular and cell-derived therapeutics for heart disease, with its CardiAMP and CardiALLO platforms utilizing Helix and Morph technologies to improve treatment outcomes for heart failure and acute myocardial infarction.
See More
